Join Satellos Bioscience for a virtual key opinion leader (KOL) event featuring Kevin M. Flanigan, MD (Nationwide Children’s Hospital & The Ohio State University College of Medicine), who will join company management to discuss the unmet need and current treatment landscape for Duchenne muscular dystrophy (DMD).

The event will provide an overview of Satellos’ SAT-3247, an oral small molecule therapy designed to restore natural muscle repair and regeneration in DMD and related conditions. SAT-3247 targets AAK1, a protein involved in muscle stem-cell signaling, a process that is disrupted in DMD due to the absence of dystrophin. The session will review results from the completed Phase 1a/b clinical trial in healthy volunteers and adults with DMD; outline TRAILHEAD, the open-label study in adult participants; and share updates on BASECAMP, the ongoing Phase 2 pediatric study.